Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefurulimab PK Study in Proteinuric Kidney Disease
NCT05314231Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- May 2023
- Modality
- Bispecific Antibodies, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gefurulimab in lupus nephritis (LN), IgA nephropathy (IgAN), primary membranous nephropathy (PMN) and 6 more, sponsored by Alexion Pharmaceuticals. Primary endpoint: Serum Concentration of ALXN1720 at Day 57. Started Jun 2022; status: completed.
02
Drugs
gefurulimab
03
Conditions
lupus nephritis (LN)IgA nephropathy (IgAN)primary membranous nephropathy (PMN)focal segmental glomerulosclerosis (FSGS)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT05314231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05314231.